Is the first patented formulation with slow release oral Pirfenidone, that offers a therapeutic anti-fibrotic and anti-inflammatory effect directly on fibrotic diseases.
Is the ideal anti-fibrotic treatment for lung and liver fibrosis, that acts rapidly and effectively, to improve the clinical indicators by repairing and regenerating damaged tissue, achieving results that improves patient's quality of life.
It represents an innovation for the treatment associated with fibrosis:
The Pirfenidone on KitosCell LP™ opens up a new path on the road of fibrotic diseases, due to the lack of efficient products to help with these diseases; Pirfenidone is a new effective and safe anti-fibrotic treatment, option.
Due to its action at cellular level, KitosCell LP™ improves tissue reparation and gives an anti-inflammatory effect for the treatment of any type of fibrosis; it prevents the formation of fibrotic lesions, diminishes the fibrosis and acumulation of fibrosis and reverts the already formed fibrosis.